Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Taps Medical Solutions to Distribute Oncotype DX in UK

NEW YORK (GenomeWeb News) — Genomic Health said today it has hired Medical Solutions to exclusively distribute its Oncotype DX breast cancer assay in the UK.
 
Chu Chang, vice president of business development at Genomic Health, said the agreement with the UK diagnostics and healthcare company is part of Genomic Health's strategy to broaden access to its test to patients outside of the US.
 
The Oncotype test predicts the likelihood of breast cancer recurrence in women with newly diagnosed, early stage invasive breast cancer. It also predicts the chance that chemotherapy will benefit “a large portion” of patients with early-stage breast cancer, the company said.
 
Genomic Health said it has service and supply agreements for the Oncotype in Israel and Japan. In the US the test is performed by CLIA-certified labs.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.